コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 r, and easier to administer than intravenous immune globulin.
2 y) without the adjunctive use of hepatitis B immune globulin.
3 of early clinical trials with intravenous Rh immune globulin.
4 ids, intravenous immunoglobulin G, or anti-D immune globulin.
5 f the 72 children were receiving intravenous immune globulin.
6 tient received variable doses of hepatitis B immune globulin.
7 ng the recommended number of doses of rabies immune globulin.
8 l consisting of rituximab and/or intravenous immune globulin.
9 n develop despite treatment with intravenous immune globulin.
10 th entecavir monotherapy without hepatitis B immune globulin.
11 eceived hepatitis A vaccine and 522 received immune globulin.
12 olated rat anti-B5 mAb (19C2) or by vaccinia immune globulin.
13 nses to conventional therapy and intravenous immune globulin.
14 s, immunosuppressive agents, and intravenous immune globulin.
15 ed, we evaluated the efficacy of intravenous immune globulin.
16 therapy with ganciclovir and cytomegalovirus immune globulin.
17 ensing TLR7 and TLR9 proliferate and secrete immune globulins.
18 more potent and broadly reactive hepatitis C immune globulins.
19 ence compromised the safety of the resulting immune globulins.
20 smapheresis every other day with intravenous immune globulin 100 mg/kg starting 1 week before the sch
21 rea) once weekly for 3 weeks and intravenous immune globulin (2 g per kilogram of body weight) in the
22 rtum cardiomyopathy treated with intravenous immune globulin (2 g/kg) with those of 11 recent histori
23 ceived conventional therapy with intravenous immune globulin, 2 g per kilogram, as well as aspirin, 8
24 vaccine (4.4%) and in 17 contacts receiving immune globulin (3.3%) (relative risk, 1.35; 95% confide
25 of 3 treated) and immunotherapy (intravenous immune globulin, 3 of 4 treated and plasmapheresis, 3 of
28 t of acute Kawasaki disease with intravenous immune globulin and aspirin reduces the risk of coronary
29 screening, including benefits of hepatitis B immune globulin and hepatitis B vaccine prophylaxis of n
31 3 despite empiric treatment with intravenous immune globulin and methylprednisolone, splenectomy was
32 =0.01 and P<0.001, respectively) between the immune globulin and placebo groups, and immune globulin
34 in the U.S. study also received intravenous immune globulin and rituximab after transplantation to p
35 suggest that the combination of intravenous immune globulin and rituximab may prove effective as a d
38 with PV who required treatment with vaccinia immune globulin and who received 2 investigational agent
39 cury from thimerosal-containing vaccines and immune globulins and deficits in neuropsychological func
42 tients do not respond to initial intravenous immune globulin, and recommendations for additional ther
44 that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning re
46 mide pulse therapy together with intravenous immune globulin before transplant and as part of a cyclo
49 he association between cytomegalovirus (CMV) immune globulin (CMVIG) and clinical outcomes in pediatr
51 ults (n = 20) 7 days after administration of immune globulin contained similar antibody levels by imm
57 antiviral therapy alone without hepatitis B immune globulin for chronic hepatitis B patients with pr
58 hemolysis after infusions of intravenous Rh immune globulin for immune thrombocytopenic purpura has
59 n, and it may be a reasonable alternative to immune globulin for postexposure prophylaxis in many sit
61 partum cardiomyopathy, patients treated with immune globulin had a greater improvement in ejection fr
63 were anti-HBs-, HbsAg- received hepatitis B immune globulin (HBIG) 10,000 IU i.v. daily for 7 days a
64 long-term antiviral and low-dose hepatitis B Immune globulin (HBIG) can effectively prevent HBV recur
68 of antiviral therapy with either hepatitis B immune globulin (HBIg) or lamivudine; however, HBV recur
69 e received high-dose intravenous hepatitis B immune globulin (HBIG) treatment with continued lamivudi
71 venous immune globulin (IGIV) or hepatitis C immune globulin (HCIG), and a third animal was not treat
72 G (IgG) subclasses from polyclonal human HIV immune globulin (HIVIG) in the neutralization of HIV-1 s
73 y by antibody combinations, we evaluated HIV immune globulin (HIVIG), and human monoclonal antibodies
74 IgG, including pharmacologic formulations of immune globulin i.v. (IGIV), contain Abs that specifical
75 the effects of commercial intravenous human immune globulin (i.v.IG) preparations and found that i.v
76 ated against hepatitis A and should be given immune globulin if they used methamphetamine with a case
77 Measles, mumps, and rubella vaccine (MMR) or immune globulin (IG) are routinely used for measles post
78 h later with anti-HCV--negative intravenous immune globulin (IGIV) or hepatitis C immune globulin (H
80 with hepatitis B vaccination and hepatitis B immune globulin in certain endemic regions as well as fa
83 Drug Administration (FDA) licensed Rh(o)(D) immune globulin intravenous (anti-D IGIV) on March 24, 1
85 We created the orphan drug Human Botulism Immune Globulin Intravenous (Human) (BIG-IV), which neut
87 hether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and
92 accumulating to indicate that intravenous Rh immune globulin is as effective, probably safer, and eas
93 The combination of rituximab and intravenous immune globulin is effective in patients with refractory
94 antiviral therapy alone without hepatitis B immune globulin is highly effective in preventing HBV re
100 ppressive mechanism of action of intravenous immune globulin (IVIG) has remained enigmatic despite th
101 as designed to determine whether intravenous immune globulin (IVIG) improves left ventricular ejectio
102 (CLL) or multiple myeloma (MM), intravenous immune globulin (IVIg) may be administered to reduce the
105 In living-donor recipients, intravenous immune globulin (IVIG) was added to the CMX evaluation t
106 gen (SLA) class I antibodies or pooled human immune globulin (IVIg) were used to reverse the effects
107 D.: We have shown that high-dose intravenous immune globulin (IVIG; 2 g/kg x2 doses)+rituximab (1 g x
108 ng human immunoglobulin G (IgG) (intravenous immune globulin [IVIG]), AAV-Go.1 had higher resistance
109 iciency characterized by low levels of serum immune globulins, lack of Ab, and reduced numbers of CD2
110 Pretreatment with bacterial polysaccharide immune globulin led to a significant reduction in coloni
111 h CVID who have mutations in TACI but normal immune globulin levels still have detectable in vitro B-
115 luate the effect of therapy with intravenous immune globulin on recovery of left ventricular function
116 ies, in random order, to receive intravenous immune globulin or placebo for three months, followed by
117 30% after the second infusion of intravenous immune globulin (P<0.001 for the comparison with the pre
118 lovir, adefovir, respiratory syncytial virus immune globulin, palivizumab, and imiquimod are discusse
119 le-center study examined whether intravenous immune globulin plus rituximab could reduce anti-HLA ant
120 corticosteroids, cidofovir, and intravenous immune globulin, PML progressed rapidly, rendering the p
121 s 412 to 426, as it did with an HCV-specific immune globulin preparation, which was derived from the
122 ng and protective antibodies in experimental immune globulin preparations made from anti-HCV-positive
123 containing preservative used in vaccines and immune globulin preparations, is associated with neurops
125 long been considered safe until a commercial immune globulin product, Gammagard, prepared from plasma
126 ing in cytokine secretion, IgG class switch, immune globulin production, and potentially, the preserv
128 groups indicate that hepatitis A vaccine and immune globulin provided good protection after exposure.
129 nsplant patients, and valganciclovir and CMV immune globulin reduce rejection rates and cardiovascula
130 were given respiratory syncytial virus (RSV) immune globulin (RSVIG) at the time of transplantation a
132 munodeficiency who was receiving intravenous immune globulin suddenly had paralysis of all four limbs
133 bo-controlled trial of cytomegalovirus (CMV) immune globulin that included 146 patients who underwent
134 at immunity may be augmented by vaccines and immune globulins that include strong antibody responses
135 ong-term protection conferred by hepatitis A immune globulin, the efficacy of a single injection (20
138 Anti-GAD65 antibody titers declined after immune globulin therapy but not after placebo administra
139 tivity scores decreased substantially during immune globulin therapy but rebounded during placebo adm
140 thylprednisolone to conventional intravenous immune globulin therapy for the routine primary treatmen
141 the immune globulin and placebo groups, and immune globulin therapy had a significant direct treatme
142 remains unknown, but fortunately intravenous immune globulin therapy has proved to be effective at re
145 or Kawasaki disease resistant to intravenous immune globulin therapy is an area of research and contr
146 stemic inflammation, but despite intravenous immune globulin therapy, coronary-artery abnormalities d
147 d the administration of low-dose intravenous immune globulin to desensitize 211 HLA-sensitized patien
148 we report a novel approach using intravenous immune globulin to modulate anti-HLA antibody and improv
151 Penicillin, clindamycin, and intravenous immune globulin (Venoglobulin-S; IVIG) alone and in comb
152 neutralizing determinants and that vaccinia immune globulin (VIG) derived from Dryvax recipients con
154 h improved safety profiles, and new vaccinia immune globulin (VIG) products, there is an immediate ne
156 r ejection fraction in patients treated with immune globulin was significantly greater than in the co
158 IV-1-infected patients as well as pooled HIV immune globulin were selectively depleted of antibodies
160 lar damage in dermatomyositis by intravenous immune globulin which appears to intercept the assembly
161 A virus has not been compared directly with immune globulin, which is known to be highly effective i
162 tinfection passive treatment with polyclonal immune globulin with high neutralizing titers against SI
163 comparing conventional doses of intravenous immune globulin with the most promising dose range for i
164 e-appropriate dose of hepatitis A vaccine or immune globulin within 14 days after exposure to patient
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。